Compared with minimally comorbid diabetes, the cancer-cardiometabolic high-burden multimorbidity phenotype was associated with increased 10-year all-cause mortality (aHR 1.97; 95% CI 1.80-2.15).
Cohort (n=28,043)
Do specific multimorbidity phenotypes increase the risk of 10-year all-cause mortality in adults with diabetes compared to minimally comorbid diabetes?
Latent class analysis-derived multimorbidity phenotypes effectively stratify 10-year all-cause mortality risk in adults with diabetes beyond single-condition approaches.
Hazard Ratio: 1.97 (95% CI 1.8–2.15)
Introduction and Objective: Multimorbidity is common in diabetes and affects long-term survival. We aimed to identify multimorbidity phenotypes and their link to 10-year all-cause mortality. Methods: We applied latent class analysis to 28,043 adults with diabetes using 22 comorbidity indicators and identified 4 multimorbidity phenotypes. Multivariable-adjusted Cox models were fitted. Results: Mortality was 19.1 per 1,000 person-years. Compared with minimally comorbid diabetes, the aHR for mortality risk increased across clusters of multimorbidity: hypertension-predominant cardiometabolic (1.24, 95% CI 1.16-1.32), high inflammatory and psycho-metabolic burden (1.48, 95% CI 1.33-1.64), and cancer-cardiometabolic high-burden (1.97, 95% CI 1.80-2.15). Conclusion: LCA-derived phenotypes capture mortality risk beyond single-condition approaches in diabetes. Disclosure J. Calvo-Marin: Speaker's Bureau; Current; Novo Nordisk, AstraZeneca, Abbott Diabetes, Roche Diabetes Care. F. Ruiz Salazar: Speaker's Bureau; Current; Abbott Diagnostics, AstraZeneca, Novo Nordisk A/S. Advisory Panel; Current; Roche Diagnostics. V. Mora-Gomez: None. M. Lutz: None. G. Torrealba-Acosta: None.
Calvo-Marín et al. (Fri,) conducted a cohort in Diabetes (n=28,043). Cancer-cardiometabolic high-burden multimorbidity phenotype vs. Minimally comorbid diabetes was evaluated on 10-year all-cause mortality (aHR 1.97, 95% CI 1.80-2.15). Compared with minimally comorbid diabetes, the cancer-cardiometabolic high-burden multimorbidity phenotype was associated with increased 10-year all-cause mortality (aHR 1.97; 95% CI 1.80-2.15).